Special Issue "Tuberculosis Vaccine Research and Development"
A special issue of Pharmaceutics (ISSN 1999-4923).
Deadline for manuscript submissions: closed (3 July 2020).
2. School of Veterinary Medicine, University of Surrey, VSM Building, Daphne Jackson Rd, Guildford GU2 7AL, UK
Interests: TB vaccine development and evaluation; animal-alternative laboratory models of host–pathogen interaction; disease interventions
Tuberculosis is one of the biggest threats to the health, welfare, and productivity of humans and animals globally. It causes more human deaths than any other infectious organism. The prevalence of antibiotic resistance among human cases and the cost and logistical challenges associated with controlling the disease in animals make a compelling case for continued efforts to employ a vaccination in combatting the disease.
While a vaccine for tuberculosis in the form of Bacillus Calmette–Guérin (BCG) has been around for nearly a century, it is not universally effective in people and is rarely used in animals. The World Health Organisation (WHO) has the ambitious aim of ending the global tuberculosis epidemic by 2030. It is now recognized that this is unlikely unless tuberculosis in animals is also addressed at the same time.
Progress with vaccination against tuberculosis is both difficult and slow and many hurdles remain. These include (1) identifying a more efficacious prophylactic vaccine than BCG alone; (2) a vaccine that can be used post-exposure to contain or remove the latent infection with tuberculosis, thought to exist in a third of the world’s population; and (3) vaccines and associated diagnostic tests for use in animals. A clear roadmap towards identifying, testing, licensing, and deploying such vaccines is required, together with sustained funding at a global level.
This Special Issue will highlight current research activities in the research and development of tuberculosis vaccines. We particularly encourage submissions relating to vaccine formulation (such as DNA, subunit, recombinant, and nano- and micro-particles) and different delivery modalities (such as mucosal, aerosol, transdermal) and the evaluation of their safety and efficacy in animal models and target species.
Prof. Mark Chambers
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.